S&P 500   2,954.22 (-0.82%)
DOW   25,409.36 (-1.39%)
QQQ   205.80 (+0.08%)
AAPL   273.36 (-0.06%)
FB   192.47 (+1.43%)
MSFT   162.01 (+2.42%)
GOOGL   1,339.25 (+1.85%)
AMZN   1,883.75 (-0.03%)
CGC   18.78 (+1.84%)
NVDA   270.07 (+6.92%)
BABA   208.00 (+1.45%)
MU   52.56 (+3.91%)
GE   10.88 (+4.72%)
TSLA   667.99 (-1.62%)
AMD   45.48 (+3.34%)
T   35.22 (-1.43%)
ACB   1.34 (-7.59%)
F   6.96 (-0.14%)
NFLX   369.03 (-0.72%)
PRI   111.34 (-3.00%)
BAC   28.50 (-2.16%)
GILD   69.36 (-4.54%)
DIS   117.65 (-0.33%)
S&P 500   2,954.22 (-0.82%)
DOW   25,409.36 (-1.39%)
QQQ   205.80 (+0.08%)
AAPL   273.36 (-0.06%)
FB   192.47 (+1.43%)
MSFT   162.01 (+2.42%)
GOOGL   1,339.25 (+1.85%)
AMZN   1,883.75 (-0.03%)
CGC   18.78 (+1.84%)
NVDA   270.07 (+6.92%)
BABA   208.00 (+1.45%)
MU   52.56 (+3.91%)
GE   10.88 (+4.72%)
TSLA   667.99 (-1.62%)
AMD   45.48 (+3.34%)
T   35.22 (-1.43%)
ACB   1.34 (-7.59%)
F   6.96 (-0.14%)
NFLX   369.03 (-0.72%)
PRI   111.34 (-3.00%)
BAC   28.50 (-2.16%)
GILD   69.36 (-4.54%)
DIS   117.65 (-0.33%)
S&P 500   2,954.22 (-0.82%)
DOW   25,409.36 (-1.39%)
QQQ   205.80 (+0.08%)
AAPL   273.36 (-0.06%)
FB   192.47 (+1.43%)
MSFT   162.01 (+2.42%)
GOOGL   1,339.25 (+1.85%)
AMZN   1,883.75 (-0.03%)
CGC   18.78 (+1.84%)
NVDA   270.07 (+6.92%)
BABA   208.00 (+1.45%)
MU   52.56 (+3.91%)
GE   10.88 (+4.72%)
TSLA   667.99 (-1.62%)
AMD   45.48 (+3.34%)
T   35.22 (-1.43%)
ACB   1.34 (-7.59%)
F   6.96 (-0.14%)
NFLX   369.03 (-0.72%)
PRI   111.34 (-3.00%)
BAC   28.50 (-2.16%)
GILD   69.36 (-4.54%)
DIS   117.65 (-0.33%)
S&P 500   2,954.22 (-0.82%)
DOW   25,409.36 (-1.39%)
QQQ   205.80 (+0.08%)
AAPL   273.36 (-0.06%)
FB   192.47 (+1.43%)
MSFT   162.01 (+2.42%)
GOOGL   1,339.25 (+1.85%)
AMZN   1,883.75 (-0.03%)
CGC   18.78 (+1.84%)
NVDA   270.07 (+6.92%)
BABA   208.00 (+1.45%)
MU   52.56 (+3.91%)
GE   10.88 (+4.72%)
TSLA   667.99 (-1.62%)
AMD   45.48 (+3.34%)
T   35.22 (-1.43%)
ACB   1.34 (-7.59%)
F   6.96 (-0.14%)
NFLX   369.03 (-0.72%)
PRI   111.34 (-3.00%)
BAC   28.50 (-2.16%)
GILD   69.36 (-4.54%)
DIS   117.65 (-0.33%)
Log in

NASDAQ:EYPT - Eyepoint Pharmaceuticals Stock Price, Forecast & News

$1.29
-0.02 (-1.53 %)
(As of 02/28/2020 04:00 PM ET)
Today's Range
$1.21
Now: $1.29
$1.32
50-Day Range
$1.29
MA: $1.74
$2.05
52-Week Range
$1.19
Now: $1.29
$2.72
Volume1.17 million shs
Average Volume791,490 shs
Market Capitalization$139.47 million
P/E RatioN/A
Dividend YieldN/A
Beta1.58
EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis. Read More…

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EYPT
CUSIPN/A
Phone833-393-7646

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.96 million

Profitability

Net Income$-53,170,000.00
Net Margins-409.07%

Miscellaneous

Employees55
Market Cap$139.47 million
Next Earnings Date3/12/2020 (Estimated)
OptionableOptionable

Receive EYPT News and Ratings via Email

Sign-up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter.


Eyepoint Pharmaceuticals (NASDAQ:EYPT) Frequently Asked Questions

What is Eyepoint Pharmaceuticals' stock symbol?

Eyepoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT."

How were Eyepoint Pharmaceuticals' earnings last quarter?

Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) announced its earnings results on Thursday, November, 7th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by $0.01. The business earned $2.51 million during the quarter, compared to the consensus estimate of $4.81 million. Eyepoint Pharmaceuticals had a negative return on equity of 250.32% and a negative net margin of 409.07%. View Eyepoint Pharmaceuticals' Earnings History.

When is Eyepoint Pharmaceuticals' next earnings date?

Eyepoint Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Eyepoint Pharmaceuticals.

What guidance has Eyepoint Pharmaceuticals issued on next quarter's earnings?

Eyepoint Pharmaceuticals issued an update on its FY 2019 Pre-Market earnings guidance on Thursday, January, 23rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $19.3-20 million, compared to the consensus revenue estimate of $17.9 million.

What price target have analysts set for EYPT?

4 brokerages have issued 1 year price targets for Eyepoint Pharmaceuticals' shares. Their forecasts range from $4.00 to $5.00. On average, they anticipate Eyepoint Pharmaceuticals' share price to reach $4.38 in the next year. This suggests a possible upside of 239.1% from the stock's current price. View Analyst Price Targets for Eyepoint Pharmaceuticals.

What is the consensus analysts' recommendation for Eyepoint Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyepoint Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eyepoint Pharmaceuticals.

Has Eyepoint Pharmaceuticals been receiving favorable news coverage?

Media headlines about EYPT stock have been trending extremely negative this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Eyepoint Pharmaceuticals earned a media sentiment score of -4.1 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Eyepoint Pharmaceuticals.

Who are some of Eyepoint Pharmaceuticals' key competitors?

What other stocks do shareholders of Eyepoint Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eyepoint Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), XOMA (XOMA), AcelRx Pharmaceuticals (ACRX), Catalyst Pharmaceuticals (CPRX), Opko Health (OPK), Progenics Pharmaceuticals (PGNX), Synergy Pharmaceuticals (SGYP), Agile Therapeutics (AGRX), Verastem (VSTM) and Amarin (AMRN).

Who are Eyepoint Pharmaceuticals' key executives?

Eyepoint Pharmaceuticals' management team includes the folowing people:
  • Ms. Nancy S. Lurker, Pres, CEO & Director (Age 62)
  • Mr. Leonard S. Ross, VP of Fin. & Chief Accounting Officer (Age 69)
  • Dr. Dario A. Paggiarino, VP & Chief Medical Officer (Age 62)
  • Mr. David J. Price, Chief Financial Officer (Age 56)
  • Mr. Marty Nazzaro, Sr. VP of Operations

Who are Eyepoint Pharmaceuticals' major shareholders?

Eyepoint Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include State Street Corp (1.02%), Essex Investment Management Co. LLC (0.76%), Geode Capital Management LLC (0.76%), Integrated Advisors Network LLC (0.32%), Grimes & Company Inc. (0.09%) and UBS Group AG (0.08%). Company insiders that own Eyepoint Pharmaceuticals stock include Douglas Evan Godshall, Ew Healthcare Partners, LP, George Elston, Jay S Duker, John B Landis and Nancy Lurker. View Institutional Ownership Trends for Eyepoint Pharmaceuticals.

Which institutional investors are selling Eyepoint Pharmaceuticals stock?

EYPT stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund. View Insider Buying and Selling for Eyepoint Pharmaceuticals.

Which institutional investors are buying Eyepoint Pharmaceuticals stock?

EYPT stock was purchased by a variety of institutional investors in the last quarter, including Integrated Advisors Network LLC, State Street Corp, Grimes & Company Inc., UBS Group AG, Essex Investment Management Co. LLC, Barclays PLC, Geode Capital Management LLC and Goldman Sachs Group Inc.. Company insiders that have bought Eyepoint Pharmaceuticals stock in the last two years include Douglas Evan Godshall, Ew Healthcare Partners, LP, George Elston, Jay S Duker, John B Landis and Nancy Lurker. View Insider Buying and Selling for Eyepoint Pharmaceuticals.

How do I buy shares of Eyepoint Pharmaceuticals?

Shares of EYPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Eyepoint Pharmaceuticals' stock price today?

One share of EYPT stock can currently be purchased for approximately $1.29.

How big of a company is Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals has a market capitalization of $139.47 million and generates $2.96 million in revenue each year. The company earns $-53,170,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Eyepoint Pharmaceuticals employs 55 workers across the globe.View Additional Information About Eyepoint Pharmaceuticals.

What is Eyepoint Pharmaceuticals' official website?

The official website for Eyepoint Pharmaceuticals is http://eyepointpharma.com/.

How can I contact Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals' mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The company can be reached via phone at 833-393-7646 or via email at [email protected]


MarketBeat Community Rating for Eyepoint Pharmaceuticals (NASDAQ EYPT)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  390 (Vote Outperform)
Underperform Votes:  314 (Vote Underperform)
Total Votes:  704
MarketBeat's community ratings are surveys of what our community members think about Eyepoint Pharmaceuticals and other stocks. Vote "Outperform" if you believe EYPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel